



**Supplementary figure 1. Effect of exogenous trypsin and harvesting method on APMV3 and APMV3/S-6P yields in Vero cells.** Sub-confluent wells of Vero cells in 6-well plates were inoculated in quadruplicate with APMV3 or APMV3/S-6P at an MOI of 1 PFU/cell. After 2 h incubation, Vero cells were washed once with Opti-MEM and replenished with Opti-MEM containing 1% L-glutamine with (+) or without (-) 2% TrypLE Select, as indicated (two wells per condition). To determine the titers of virus released from the infected cells (“Media”), 1 ml of the tissue culture media was harvested at 24 hpi from duplicate wells per virus per condition, clarified by brief centrifugation (3 min at 1,500 rpm), and snap-frozen. To determine the titers of released plus cell-associated virus (“Media with cells”), the monolayers (duplicate wells per virus per condition) were scraped into the 1 ml left of media, and the suspensions were gently vortexed for 1 min and clarified by brief centrifugation (3 min at 1,500 rpm), after which the clarified supernatants were aliquoted and snap-frozen. Virus titers were determined later in duplicate by immunoplaque assay on Vero cells at 37°C as described above. Means with SD from duplicate wells are shown. \*\*\*\* =  $p \leq 0.0001$ , two-way ANOVA with Tukey post-hoc test.




**Supplementary figure 2. Expression of virus proteins *in vitro*.** Viral protein expression in Vero (a-c) and A549 (d-e) cells. From the time course experiment described in Fig. 1e and 1f, Vero and A549 cells that had been infected in quadruplicate with an MOI of 0.01 PFU/cell of the indicated virus were harvested at 8 h intervals from 8 to 80 hpi. Two wells per time point were harvested for analysis of cell-associated viral proteins by Western blotting (one well) and flow cytometry (one well, Vero cells only). (a, b, d and e) Western blotting time course. The APMV3 N (a, d) and SARS-CoV-2 S (b, e) protein bands were visualized by Western blotting using a primary rabbit anti-APMV3 serum and a primary goat anti-SARS-CoV-2 S serum, respectively, and labeled with infrared dye-conjugated secondary antibodies (see Materials and Methods). The level of expression of each protein band was normalized to  $\beta$ -actin blotted from a replicate gel lane of the same sample, and expressed as fluorescence intensity. (c) Flow cytometry time course. The percentage of live single SARS-CoV-2 S-expressing cells in APMV3/S-6P-infected Vero cells was determined by flow cytometry using a PE-conjugated CR3022 anti-SARS-CoV-2 S human monoclonal antibody. (f, g) In an additional set of

three independent experiments, Vero (f) and A549 (g) cells were infected with the indicated virus using an MOI of 1 or 10 PFU/cell. At 24 hpi, cells were harvested and stained using the PE-conjugated CR3022 anti-SARS-CoV-2 S monoclonal antibody, as described above. Cells were analyzed by flow cytometry and the % of live single cells expressing SARS-CoV-2 S was determined. The mean and SD are shown.




**Supplementary figure 3. Gating strategy to identify SARS-CoV-2 spike-expressing cells described in supplementary figure 2c, f and g.** Representative flow cytometry dot plots and histogram of A549 cells describing the typical gating strategy used to identify SARS-CoV-2 spike-expressing cells. Forward and size scatter areas were first used to identify intact cells. Live cells were next gated based on a live/dead staining. Then, singlets were selected using a gate based on forward scatter height and forward scatter area. The SARS-CoV-2 S-expressing cells were identified using a PE-conjugated human CR3022 mAb and expressed as a percentage of live single cells.

### Experiment #1



**Supplementary figure 4. Immunogenicity of APMV3 and APMV3/S-6P in hamsters (from Experiment #1).** From Experiment #1 (as shown in the timeline in Fig. 3a) sera were collected on day 26 pi from 21 hamsters per group that had been inoculated on day 0 with 6 log<sub>10</sub> PFU of APMV3/S-6P or APMV3. The sera were analyzed as follows: (a) ND<sub>50</sub> titers expressed in log<sub>10</sub> against SARS-CoV-2 WA1/2020, evaluated on Vero E6 cells. The limit of detection, indicated by a dotted line, is 0.75 log<sub>10</sub>. (b and c) End-point ELISA titers expressed in log<sub>10</sub> of serum IgG to the full-length S (b) and the RBD of S (c). The limit of detection, indicated by a dotted line, is 2 log<sub>10</sub>. (d) Titers of APMV3-neutralizing antibodies in sera from day -11 and 26, expressed in log<sub>10</sub> 60% plaque reduction neutralization titer (PRNT<sub>60</sub>). The limit of detection is indicated by a dotted line (1 log<sub>10</sub>). In each graph, the mean and SD are shown. \*\*\*\* =  $p \leq 0.0001$ , Mann-Whitney test (a-c) or two-way ANOVA with Sidak post-hoc test (d).



**Supplementary figure 5. Uncropped and unprocessed scan that was used to generate Fig. 2a, showing viral protein expression in Vero cells.** From the experiment described in Fig. 1e and 1f, one additional replicate well of Vero cells per virus, which had been infected with an MOI of 0.01 PFU/cell of the indicated virus, was harvested at 40, 48, and 56 hpi, and cell lysates were prepared and analyzed by SDS-PAGE under reducing and denaturing conditions. The APMV3 N and SARS-CoV-2 S protein bands were visualized by Western blotting using primary rabbit anti-APMV3 serum and goat anti-SARS-CoV-2 S serum, followed by incubation with IRDye-conjugated secondary antibodies and infrared imaging (see Materials and Methods). A mouse anti- $\beta$ -actin antibody was included to provide a loading control. Panels were derived from the same gel. Lanes 4-6 (cells harvested at 48 hpi) were used to generate Fig. 2a.